ICAD - iCAD Quarterly EPS earnings growth
Cloud-based AI diagnostic delivery accelerates diagnosis times, driving interest in the asset. The shift in the quarterly EPS level visualizes this trend, where the value 33.30 reflects the current magnitude. iCAD, Inc. (ICAD) focuses on implementing automated mammography screening for clinics, yet high R&D costs and a revenue deficit are depleting the company's cash reserves.
%20Earnings%20per%20share%20growth%20in%20annualized%20terms%20for%20the%20last%20twelve%20months&width=1200&height=400&colorIndex=0&v=mwczyyub.rjb-7czcsu8&start=20220704&end=20261112&filename=GURU_Markets_-_ICAD_-_iCAD-Inc._-_Earnings-per-share-growth-in-annualized-terms-for-the-last-twelve-months "iCAD Inc. (ICAD): Quarterly EPS earnings growth from 07/04/2022 to 08/02/2025 | 👁️GURU.Markets👁️")
ICAD (iCAD, Inc.): analytical breakdowns and indicator data
- market value and analyst target forecast:
- market capitalization statistics:
- balance sheet net asset value indicators:
- company liabilities and liquidity data:
- earnings and valuation multiples indicators:
ICAD - Company Profit|Projected Future Earnings iCAD, Inc.|ICAD - Price to Earnings Ratio|Projected Price to Earnings icadmed.com|ICAD - Growth-Adjusted Market Cap to Net Income|EV/EBITDA Multiple iCAD Corp|ICAD - Operating income before deduction of amortization|Net earnings per share (EPS TTM) iCAD|ICAD - Net earnings per share for the last 12 months|Quarterly EPS earnings growth icadmed.com|ICAD - Earnings growth in current year|Earnings growth forecast for next year iCAD, Inc.
Summary company analysis:iCAD Inc., ICAD
Earnings per share dynamics determine the long-term business valuation trend by filtering out short-term market noise. The percentage change in quarterly EPS measures net income growth rates relative to the previous period, reflecting the scaling efficiency of the iCAD, Inc. (ICAD) SaaS model in AI-powered breast cancer diagnostics and the impact of new B2B contracts on the final profitability of each share.
Who iCAD, Inc. competes with
BeiGene (ONC) - Year-over-year earnings per share growth for the last twelve months|Halozyme Therapeutics, Inc. - Year-over-year earnings per one share growth for the last 12 months|RVMD (RevMed) - Quarterly EPS earnings growth|Earnings per share growth in annualized terms for the last twelve months Ascentage Pharma Corp AAPG|Quarterly EPS earnings growth CGON|Year-over-year net earnings per share change for the last twelve months urogen.com|Quarterly EPS earnings growth BCAX (Bicara Therapeutics)|PSNL - Year-over-year net earnings per share growth for the last 12 months|Erasca Corp - Quarterly EPS earnings growth|DCTH - Quarterly EPS earnings growth|YMAB: Quarterly EPS earnings growth|Year-over-year earnings per share growth for the last 12 months AURA|Year-over-year net earnings per share growth for the last 12 months CADL|ARAY: Year-over-year earnings per one share growth for the last 12 months|Quarterly EPS earnings growth SLS|Year-over-year net earnings per share change for the last twelve months Actuate Therapeutics Inc|Year-over-year earnings per share growth for the last twelve months Citius Oncology, Inc. CTOR|HURA: Year-over-year earnings per share growth for the last 12 months|Protara Therapeutics, Inc. - Quarterly EPS earnings growth|Fate Therapeutics Inc (FATE) - Year-over-year net earnings per share growth for the last 12 months|WHWK (aadibio.com) - Year-over-year net earnings per share growth for the last 12 months|TCRX - Year-over-year net earnings per share change for the last twelve months|CSBR (Champions Oncology Inc) - Quarterly EPS earnings growth|XBiotech USA (XBIT) - Year-over-year net earnings per share change for the last twelve months|Quarterly EPS earnings growth CVM|Year-over-year net earnings per share growth for the last 12 months OS Therapies Inc. OSTX|Quarterly EPS earnings growth RADX (Radiopharm Theranostics)|Quarterly EPS earnings growth Artiva Biotherapeutics Inc. ARTV|Adlai Nortye Limited - Quarterly EPS earnings growth|VERU (verupharma.com) - Year-over-year earnings per share growth for the last 12 months|TPST: Quarterly EPS earnings growth|Year-over-year net earnings per share growth for the last 12 months Xilio Therapeutics|RENB (Renovaro Biosciences) - Quarterly EPS earnings growth|Quarterly EPS earnings growth Mural Bio|Year-over-year earnings per share growth for the last twelve months Kairos Pharma Ltd (KAPA)|onkuretherapeutics.com - Year-over-year earnings per share growth for the last 12 months|Quarterly EPS earnings growth GDTC (CytoMed Therapeutics Limited)|CRIS - Year-over-year net earnings per share growth for the last 12 months|Apollomics Corp - Quarterly EPS earnings growth|Earnings per share growth in annualized terms for the last twelve months Tharimmune Corporation|advanbiomed.com (ADVB) - Year-over-year earnings per share growth for the last twelve months|genprex.com - Year-over-year earnings per one share growth for the last 12 months|Year-over-year net earnings per share growth for the last 12 months CLDI|SBFM: Year-over-year earnings per one share growth for the last 12 months|Quarterly EPS earnings growth XBIO|Year-over-year net earnings per share growth for the last 12 months Salarius Pharma SLRX|Purple Biotech - Year-over-year net earnings per share growth for the last 12 months|Quarterly EPS earnings growth American Oncology Network Inc AONC|BGNE - Year-over-year earnings per share growth for the last twelve months|Year-over-year earnings per one share growth for the last 12 months CKPT (Checkpoint Therapeutics Inc.)|ELEV: Quarterly EPS earnings growth|Earnings per share growth in annualized terms for the last twelve months Ikena Oncology (IKNA)|NTBL (Notable Labs, Ltd.) - Quarterly EPS earnings growth|Viracta (VIRX) - Year-over-year net earnings per share change for the last twelve months|Quarterly EPS earnings growth MOR|Year-over-year net earnings per share growth for the last 12 months NAYA Biosciences Inc NAYA|Quarterly EPS earnings growth AAPGV (Ascentage Pharma Group Ltd)
